NCT00876044 - A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

November 30, 2010

Conditions

Cancer

Interventions

DRUG

aflibercept (AVE0005)

Intravenous route

DRUG

placebo

Intravenous route

Trial Locations (7)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Istanbul